Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma

Trial Profile

Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs CJM 112 (Primary) ; LCL 161 (Primary) ; PDR 001 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 24 Dec 2018 to 1 Jun 2020.
    • 08 Aug 2017 Planned primary completion date changed from 24 Dec 2018 to 1 Jun 2020.
    • 08 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top